Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) POSTED

Grants.gov opportunity · National Institutes of Health · view on grants.gov ↗

Key facts

Opportunity ID: 357343
Opportunity number: PAR-25-226
Agency: National Institutes of Health
Status: posted
Document type: synopsis
Open date: 11/22/2024
Close date: 11/19/2026
CFDA codes: 93.242